• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

IJERPH, Vol. 17, Pages 9542: Depressed Mood after Stroke: Predictive Factors at Six Months Follow-Up
Conclusion: PSD is highly prevalent after stroke and is associated with the severity, left location of the stroke, and the degree of disability at discharge. Its impact justifies the evaluation and early treatment that still continues to be a challenge today.
Source: International Journal of Environmental Research and Public Health - December 20, 2020 Category: Environmental Health Authors: Fidel L ópez-Espuela Ra úl Roncero-Martín Maria de la Luz Canal-Mac ías Jose M. Moran Vicente Vera Adela Gomez-Luque Alejandro Lendinez-Mesa Juan Diego Pedrera-Zamorano Ignacio Casado-Naranjo Jesus Lavado-Garc ía Tags: Article Source Type: research

Predicted Impact of Recent Patent Foramen Ovale Closure Trials on Management of Cryptogenic Stroke
Background: The indication for percutaneous closure of patent foramen ovale (PFO) has recently changed, following evidence that closure is superior to medical treatment alone in preventing recurrent stroke in cryptogenic stroke patients aged ≤60 years. We aimed to determine the impact of updated criteria on the management of stroke or transient ischemic attack (TIA) at our institution.
Source: Heart, Lung and Circulation - June 23, 2019 Category: Cardiology Authors: P. Trevella, L. Sanders, D. Jin, J. Gutman, MacA. Isaac, S. Palmer Tags: 667 Source Type: research

Depressed mood after stroke: predictive factors at six months follow-up - L ópez-Espuela F, Roncero-Martín R, Canal-Macías ML, Moran JM, Vera V, Gomez-Luque A, Lendinez-Mesa A, Pedrera-Zamorano JD, Casado-Naranjo I, Lavado-García J.
We aimed to know the prevalence of post-stroke depression (PSD) in our context, identify the variables that could predict post-stroke depression, by using the Hamilton Depression Rating Scale, occurring within six months after stroke, and identify patien...
Source: SafetyLit - January 11, 2021 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Chronic Kidney Disease and Third-Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year.
In conclusion, the use of third-generation P2Y12 inhibitors among non-CKD patients was associated with better outcomes. CKD patients receiving third-generation P2Y12 inhibitors treatment showed no statistically significant lower mortality and thrombotic events. Bleeding risk was not increased with the use of third-generation P2Y12 inhibitors in either group of patients. PMID: 30207603 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Pharmacology - September 12, 2018 Category: Drugs & Pharmacology Authors: Tello-Montoliu A, Ruiz-Nodar JM, Esteve-Pastor MA, Véliz-Martínez A, Orenes-Piñero E, Macías-Villanego MJ, Lozano T, Carrillo-Alemán L, Vicente-Ibarra N, Pernias-Escrig V, Martínez-Martínez JG, Rivera-Caravaca JM, Marín F Tags: J Clin Pharmacol Source Type: research

The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal.
Abstract In cardiovascular disease (CVD), biomarkers (i.e., "biological markers") could have multiple roles in understanding the complexity of cardiovascular (CV) pathophysiology and to offer an integrated approach to management. Biomarkers could help in daily practice as a diagnostic tool, to monitor therapy response, to assess prognosis and as early marker of CV damage, or to stratify risk. In recent years, the role of biomarkers in CVD is even more relevant and some have recently been included in clinical management guideline recommendations. The aim of this review is to discuss the recommendations in clinical ...
Source: Thrombosis and Haemostasis - September 8, 2019 Category: Hematology Authors: Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F Tags: Thromb Haemost Source Type: research

Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy.
Authors: Rivera-Caravaca JM, Esteve-Pastor MA, Camelo-Castillo A, Ramírez-Macías I, Lip GYH, Roldán V, Marín F Abstract INTRODUCTION: Oral anticoagulants (OAC) reduce stroke/systemic embolism and mortality risks in atrial fibrillation (AF). However, there is an inherent bleeding risk with OAC, where intracranial hemorrhage (ICH) is the most feared, disabling, and lethal complication of this therapy. Therefore, the optimal management of OAC-associated ICH is not well defined despite multiple suggested strategies. AREAS COVERED: In this review, the authors describe the severity and risk factors for OAC-associ...
Source: Expert Opinion on Pharmacotherapy - July 15, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Cardiovascular Progerin Suppression and lamin A Restoration Rescues Hutchinson-Gilford Progeria Syndrome
Conclusions: HGPSrev mice constitute a new experimental model for advancing knowledge of HGPS. Our findings suggest that it is never too late to treat HGPS, although benefit is much more pronounced when progerin is targeted in mice with mild symptoms. Despite the broad expression pattern of progerin and its deleterious effects in many organs, restricting its suppression to VSMCs and cardiomyocytes is sufficient to prevent vascular disease and normalize lifespan.PMID:34694158 | DOI:10.1161/CIRCULATIONAHA.121.055313
Source: Circulation - October 25, 2021 Category: Cardiology Authors: Amanda S ánchez-López Carla Espin ós-Estévez Cristina Gonz ález-Gómez Pilar Gonzalo Mar ía J Andrés-Manzano V íctor Fanjul Raquel Riquelme-Borja Magda R Hamczyk Álvaro Macías Lara Del Campo Emilio Camafeita Jes ús Vázquez Anna Barkaway Lo ïc Source Type: research